We may explore using more of the family data instead of only using SNPs. Other sources of information could be captured, such as the copy number variants (CNVs) [88], [89]. It is also suggested that non-genetic risk factors tend to raise the attention for complex traits and should also be incorporated into the genetic studies. Meanwhile, it is likely that COGA will obtain GWAS data in the relatives so that we can evaluate the efficiency of inference versus having GWAS genotypes available. Power calculation and sample size estimation of the new statistics are needed for general use. Due to the uncertainty inherent to the inference procedure, we plan to develop better strategies for generating dosage probabilities.
